Product Research
Paclitaxel
Docetaxel
Vinorelbine
Ifosfamide
Mesna
Pirarubicin
Aclarubicin
Adriamycin
Daunorubicin
Vincristine
Bleomycin
Lastet



 

Vinorelbine ditartrate for injection (NVB) is a new monobasic vinblastine sulfate drug developed by Pierre Fabre. The molecule target is the dynamic balance of microtubule protein / microtubule. It can combine with microtubule protein so as to form an obstacle in karyo-genetic division process and induce microtubule to disaggregate so as to stop the division growth of tumor cells at mitosis metaphase, and then generates its anti-tumor effects.

It is shown in the Extra-organ anti-tumor researches that vinorelbine has fairly strong effect to human body tumor cell line such as lung cancer (small cell or non-small cell), breast cancer, leukemia, colon carcinoma and so on.

The main applicable symptoms of vinorelbine are in the following: non-small cell lung cancer, metastatic breast cancer, malignant lymphoma and late state ovarian cancer.

The Vinorelbine ditartrate for injection produced by Shenzhen Main Luck Pharmaceuticals Inc. is a kind of national basic medicines and the secondary national essential medical insurance drugs. It is trustable for the excellent quality.


 
  国家食品药品监督管理局世界卫生组织中国医学科学院深圳万维医药贸易有限公司  
  深圳万乐药业有限公司 版权所有
Copyright © 2004 Shenzhen Main Luck Phar maceuticals Inc. All right reserved
Email:wanle@wanle.com.cn
 
Home Site Map English Version